All the Therapeutic System Drugs
Thrombolytic Agent. Alteplase 20 mg/vial, 50 mg/Vial. VIAL. (pwdr.+ solvent for sol. for inject./
infus.): 1 + 1 vial of solvent. Dosage
must be ajust. individ according to pt.
Acute MI: In adults for the lysis of thrombi
obstruct. coron. arteries, the reduction of
infarct size, the improve. of ventr. func., the
reduction of the incidence of congest.
heart fail., reduct. of mortality assoc. with
AMI. Tmt. should be initiated as soon as
possible after the onset of AMI sympt.
Massive Pulmon.embol. with
of acute massive pulmonary embolism
(PE) in adults: For the lysis of acute pulm.
emboli, defined as obstruct. of blood flow
to a lobe or multiple segments of the lung,
For the lysis of pulmon. emboli
accompanied by unstable hemodynamics
e.g. fail.to maintain blood pressure
without supportive measures.
The diagnosis should be confirmed by
objective means, such as pulmon.
angiography or noninvasive procedures
such as lung scanning.For fibrinolytic
treatment of acute ischaemic stroke Tmt.
must be started as early as possible within
4.5 hrs. after onset of stroke sympt.and
after exclusion of intracr. haemorrhage by
appropriate imaging techniques (e.g.
cranial CT or other diag. imaging method
sensitive for the presence of
haemorrhage). The tmt. effect is timedependent;
therefore earlier tmt. incr. the
probability of a favourable outcome.
C/I: Hypersens. High risk cases of
haemorrhage such e.g.: Signific. bleed.
disor. at present or within the past 6
mnths. Known haemorrhage.diathesis.
Pts. receiving effective oral anticoag.
tmt., e.g. warfarin sodium. Manifest or
recent severe or dangerous bleed.
Known hist.of or suspected intracran.
haemorrhage. Suspected subarachnoid
subarachnoid haemorrhage from
aneurysm. Any history of CNS damage
(i.e. neoplasm, aneurysm, intracran./
spinal surg.). Recent (less than 10 days) traumatic external heart massage,
obstetrical delivery, recent puncture of a
non-compressible blood-vessel (e.g.
subclavian or jugular vein puncture).
Severe uncontrol.arterial hypertens.
Bact. endocarditis, pericarditis. Acute
pancreatitis. Documented ulcerative GI
dis. during the last 3 mnths.,
oesophageal varices, arterial-aneurysm,
Neoplasm with incr. bleed.risk. Severe
liver dis., includ. hep. fail., cirrhosis,
portal hypertension (oesophageal
varices) and active hepatitis. Major surg.
or signific. trauma in past 3 mnths.
Addit. contraind. in acute pulmonary
embolism, MI, acute ischaemic stroke,
Antiplatelet Agent. Tirofiban HCl Monohydrate 0.05 mg/ml. VIAL FOR INJECT: 1 x 12.5 mg/50 ml
INFUS. BAG: 1 x 12.5 mg/250 ml (0.05
mg/ml). Initial: 0.4 μg/kg/min of
diluted sol. by I.V. Then 0.1 μg/kg/min.
In comb. with heparin in unstable
ang. or non-Q-wave M.I., prevent card.
ischem. events, acute coronary syndr.
(incl. medically managed and
undergoing PTCA or atherectomy). See
Thrombin Inhibitor. Bivalirudin 250 mg/vial. VIALS (pwdr. for I.V. inject.): 1 x 10. I.V.
bolus: 1.0 mg/kg foll. by 4 hr. infus. at
rate of 2.5 mg/kg/hr. Aft. complete
initial 4 hr. infus., addition. I.V. infus.
may be initiat. at 0.2 mg/kg/hr. for up
to 20 hrs. if reqd. Use with aspirin (300
- 325 mg dly). Initiate just prior to
PTCA. May need to reduce dose and
anticoag. status monitored in pts. with
Unstable ang. undergoing percutan.
translum. coron. angioplasty (PTCA). To
be used with aspirin. See lit. for safety
C/I: Known hypersens.
Anticoagulant. Fondaparinux (sodium) 2.5 mg/0.5 ml, 0.75 mg/ 0.6 ml. PRE-FILLED SYR. (sol., for inject.): 10 x
0.5 ml x 2.5 mg, 10 x
0.6 ml x 0.75 mg. See lit.
Prevent. VTE in pts. undergoing major
orthoped. surg. lower limbs. Prevent. VTE in
pts. undergoing abdom. surg. who are at high risk thromboembol. complicats.
Prevent. VTE in medical pts. at high risk for
VTE and immobilised due to acute illness
such as card. insuffic. and/or acute respirat.
disords, and/or acute infects. or inflamm.
dis. Tmt. unstable angina or non-ST segm.
elevat. myocard. infarct. (UA/NSTEMI) in
pts. where urgent invas. manage. (PCI) not
indicat. Tmt. ST segm. elevat. myocard.
infarct. (STEMI) in pts managed with
thrombolytics or who are not to receive
other form reperfus. ther.
C/I: Hypersens., active clin. bleed., acute
bact. cardit., severe ren. fail. (creatinine
clear. <20 ml/min).